KALA BIO, Inc. - Common Stock (KALA)
1.6299
+0.0899 (5.84%)
NASDAQ · Last Trade: Oct 3rd, 10:56 AM EDT
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · October 1, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · September 30, 2025
Unusual volume stocks in Tuesday's session
Via Chartmill · September 30, 2025
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27.
Via Benzinga · September 29, 2025

KALA stock results show that Kala Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 6, 2024
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.
Via Benzinga · September 29, 2025
Kala Bio Inc. (NASDAQ: KALA) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition.
Via Benzinga · September 29, 2025
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.
Via Benzinga · September 29, 2025
The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures.
Via Stocktwits · September 29, 2025

Kala Pharmaceuticals (NASDAQ:KALA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:00 AM. Here's what investors need to know about the announcement.
Via Benzinga · May 9, 2023
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
Via Benzinga · August 21, 2025
Via Benzinga · July 11, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 22, 2025

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.
Via Stocktwits · February 12, 2025

This morning's hotter-than-expected CPI data sent the market reeling, after the annual inflation rate rose to 3% and the 12-month core inflation rate rose to 3.3%.
Via Talk Markets · February 12, 2025

KALA stock results show that Kala Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 14, 2024

KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 2, 2024

Via Benzinga · December 5, 2023

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.
Via Benzinga · July 24, 2023

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High-short interest and high-cost to borrow are among the common traits that could lead to a short squeeze.
Via Benzinga · May 15, 2023

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.
Via Benzinga · May 8, 2023